Amphastar Pharmaceuticals
AMPH
243 hedge funds and large institutions have $873M invested in Amphastar Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 82 increasing their positions, 92 reducing their positions, and 34 closing their positions.
427% more call options, than puts
Call options by funds: $2.01M | Put options by funds: $381K
16% more capital invested
Capital invested by funds: $752M → $873M (+$121M)
1.03% more ownership
Funds ownership: 69.41% → 70.43% (+1%)
0% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 34
1% less funds holding
Funds holding: 245 → 243 (-2)
11% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 92
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$8.03M |
| 2 |
CCMG
Clark Capital Management Group
Philadelphia,
Pennsylvania
|
+$7.33M |
| 3 |
AG
Algert Global
San Francisco,
California
|
+$6.94M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$6.34M |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$5.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$8.27M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$6.95M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$5.89M |
| 4 |
CI
CX Institutional
Auburn,
Indiana
|
-$5.16M |
| 5 |
BlackRock
New York
|
-$4.74M |
AMPH Hedge Fund Activity: Q3 2025 in Review
243 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q3 2025, worth a combined $873M — up 16% from $752M a quarter earlier.
Fund positioning in AMPH was balanced in Q3 2025: 34 funds opened new positions, 34 closed out, 82 added to existing stakes and 92 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $8.03M. The largest seller was Pacer Advisors, cutting an estimated $8.27M.
- 243 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q3 2025, down from 245 in Q2 2025.
- Funds reported $873M of Amphastar Pharmaceuticals stock for Q3 2025, up 16% quarter-over-quarter.
- 34 funds opened new Amphastar Pharmaceuticals positions in Q3 2025 and 34 closed out, a net change of 0 holders.
- The largest Amphastar Pharmaceuticals buyer in Q3 2025 was Arrowstreet Capital, an estimated $8.03M added.
- The largest Amphastar Pharmaceuticals seller in Q3 2025 was Pacer Advisors, an estimated $8.27M sold.
Based on aggregated 13F filings for Q3 2025.